The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 34, 2009, Pages 14711-14715

  Luciani, Fabio ^a   Sisson, Scott A ^a   Jiang, Honglin ^a   Francis, Andrew R ^b   Tanaka, Mark M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Antibiotic resistance; Approximate Bayesian computation; Bacterial evolution; Molecular epidemiology; Stochastic model

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BAYES THEOREM; COMPARATIVE STUDY; CUBA; DRUG COST; DRUG SENSITIVITY; ESTONIA; IN VIVO STUDY; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE; TUBERCULOSIS; VENEZUELA;

ALGORITHMS; ANTITUBERCULAR AGENTS; BAYES THEOREM; CUBA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESTONIA; HUMANS; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; VENEZUELA;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 70149090840     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902437106     Document Type: Article

References (29)

1. World Health Organization (2004) Anti-tuberculosis drug resistance in the world.WHO report 2004 (WHO, Geneva), Tech Rep (WHO/HTM/TB/2004.343), available at www-.who.int/tb/publications/2004/en/index.html.
2. Cohen J (2006) Infectious disease: Extensively drug-resistant TB gets foothold in South Africa. Science 313:1554.
3. Cohen T, Sommers B, Murray M (2003) The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 3:13-21.
4. Andersson DI, Levin BR (1999) The biological cost of antibiotic resistance. Curr Opin Microbiol 2:489-493.
5. Sander P, et al. (2002) Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 46:1204-1211. (Pubitemid 34415292)
6. Gagneux S, et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946.
7. Blower SM,ChouT (2004) Modeling the emergence of the 'hot zones': Tuberculosis and the amplification dynamics of drug resistance. Nat Med 10:1111-1116.
8. Cohen T, Murray M (2004) Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10:1117-1121. (Pubitemid 39424874)
9. Dye C, Williams BG, Espinal MA, Raviglione MC (2002) Erasing the world's slow stain: Strategies to beat multidrug-resistant tuberculosis. Science 295:2042-2046. (Pubitemid 34229458)
10. Kruuner A, et al. (2001) Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 39:3339-3345. (Pubitemid 32830336)
11. Bifani P, et al. (2001) Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. Emerg Infect Dis 7:842-848. (Pubitemid 33121591)
12. Wilson RW, et al. (1999) Evidence from molecular fingerprinting of limited spread of drug-resistant tuberculosis in Texas. J Clin Microbiol 37:3255-3259.
13. Post FA, et al. (2004) Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J Infect Dis 190:99-106. (Pubitemid 38858409)
14. Faustini A, Hall AJ, Perucci CA (2006) Risk factors for multidrug resistant tuberculosis in Europe: A systematic review. Thorax 61:158-163. (Pubitemid 43235434)
15. Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN (2006) Molecular epidemiology of tuberculosis: Current insights. Clin Microbiol Rev 19:658-685. (Pubitemid 44582976)
16. Lipsitch M, Levin BR (1998) Population dynamics of tuberculosis treatment: Mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 2:187-199. (Pubitemid 28123517)
17. Blower SM, Gerberding JL (1998) Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: A theoretical framework. J Mol Med 76:624-636.
18. Dye C, Williams BG (2000) Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci USA 97:8180-8185.
19. Dye C, Espinal MA (2001) Will tuberculosis become resistant to all antibiotics? Proc R Soc London Ser B 268:45-52. (Pubitemid 32127952)
20. Böttger EC, Springer B (2008) Tuberculosis: Drug resistance, fitness, and strategies for global control. Eur J Pediatr 167:141-148.
21. Sisson SA, Fan Y, Tanaka MM(2007) Sequential Monte Carlo without likelihoods. Proc Natl Acad Sci USA 104:1760-1765, and correction (2009), 10.1073/pnas.0908847106. (Pubitemid 46239852)
22. Diaz R, et al. (1998) Molecular epidemiology of tuberculosis in Cuba outside of Havana, July 1994-June 1995: Utility of spoligotyping versus IS6110 restriction fragment length polymorphism. Int J Tuberc Lung Dis 2:743-750. (Pubitemid 28429725)
23. Aristimuño L, et al. (2006) Molecular characterisation of Mycobacterium tuberculosis isolates in the first national survey of anti-tuberculosis drug resistance from Venezuela. BMC Microbiol 6:90. (Pubitemid 44631335)
24. Luciani F, Francis AR, Tanaka MM (2008) Interpreting genotype cluster sizes of Mycobacterium tuberculosis isolates typed with IS6110 and spoligotyping. Infect Genet Evol 8:182-190.
25. Tanaka MM, Francis AR (2006) Detecting emerging strains of tuberculosis by using spoligotypes. Proc Natl Acad Sci USA 103:15266-15271. (Pubitemid 44583199)
26. Basu S, et al. (2009) Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci USA 106:7672-7677.
27. Handel A, Regoes RR, Antia R (2006) The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol 2:e137. (Pubitemid 44656519)
28. Tanaka MM, Francis AR, Luciani F, Sisson SA (2006) Using approximate Bayesian computation to estimate tuberculosis transmission parameters from genotype data. Genetics 173:1511-1520. (Pubitemid 44127654)
29. World Health Organisation (2008) Implementing the WHO Stop TB Strategy: A handbook for national tuberculosis control programmes. (WHO, Geneva), Tech Rep (WHO/HTM/TB/2008.401).